 |
Testee.com - being tested ? |
 |
Home Site Map contact us |
Global Automated and Rapid Microbiological Tests Industry
NEW YORK, Dec. 8, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Global Automated and Rapid Microbiological Tests Industry http://www.reportlinker.com/p092467/Global-Automated-and-Rapid-Microbiological-Tests-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_ This report analyzes the worldwide markets for Automated and Rapid Microbiological Tests in US$ Million by the following End-Use Segments: Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests), and Non-Clinical Applications. The report provides separate comprehensive analytics for the US, Europe, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. A six-year historic analysis is also provided for these markets.The report profiles 93 companies including many key and niche players such as Abbott Laboratories, Abbott Diagnostics, Alere Inc., Becton Dickinson and Company, bioMerieux SA, bioMerieux, Inc., Bio-Rad Laboratories, Inc., Cellabs Pty Ltd, Celsis International Plc., Coris BioConcept, F. Hoffmann-La Roche Ltd., Gen-Probe Inc., MedMira Inc., Meridian Biosciences, Inc., Orasure Technologies, Inc., Orion Diagnostica Oy, Quidel Corporation, Sekisui Diagnostics, Siemens Healthcare Diagnostics, Inc., Thermo Fisher Scientific, Inc., Remel, Inc., and Oxoid Limited. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources. 1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS 1 Study Reliability and Reporting Limitations 1 Disclaimers 2 Data Interpretation & Reporting Level 3 Quantitative Techniques & Analytics 3 Product Definitions and Scope of Study 3 Clinical Applications 4 Automated Identification and Susceptibility Systems 4 Automated Blood Culture Systems 4 Automated Tuberculosis Systems 5 Streptococcal Infection Rapid Tests 5 GC/Chlamydia Rapid Tests 5 Other Automated & Rapid Microbiological Tests 5 Non-Clinical Applications 5 2. INDUSTRY OVERVIEW 6 Outlook 6 Evolutionary Battle Against Bugs Drives Market Future 6 Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market 6 Traditional Rapid Microbiological Tests Destined to Go Out With the Old 7 A Current & Future Analysis 7 Segmental Perspective 8 Clinical Applications 8 Non-Clinical Applications 8 Macro: The Big Picture 8 Deciding the Market's Future 9 A Holistic Peek into a Few Noteworthy Trends 9 Biotechnology & Rapid Microbial Tests 10 Automated & Rapid Microbiological Tests: "Current Market Stance" 11 A Business Case for Automated & Rapid Microbiological Testing 11 Near Patient Testing: An Offshoot of Rapid Microbiological Tests 12 Pros & Cons of Near Patient Testing 12 Role of Near Patient Testing in Reducing Antibiotic Resistance in Humans 13 The Pre/Post Microbial Rapid Testing Era: A Review 13 Market Structure 14 Competitive Setup of the Diverse Automated & Rapid Microbiology Products Market 14 Competitive Landscape 15 Table 1: World Market for Microorganism Identification and Resistance Tests by Leading Players (2010): Market Share Breakdown of Value Share for BioMérieux; Becton, Dickinson and Co; and Others (includes corresponding Graph/Chart) 15 Table 2: World In-Vitro Diagnostics (IVD) Market by Leading Players (2010): Market Share Breakdown for Roche, Siemens, Abbott Diagnostics, Becton Dickinson, Beckman Coulter and Others (includes corresponding Graph/Chart) 15 Table 3: World Blood Screening Market by Leading Players (2010): Market Share Breakdown for Gen-Probe/Novartis, Roche, and Others (includes corresponding Graph/Chart) 15 3. MARKET TRENDS & ISSUES 16 Advancements in Molecular Diagnostics - A Boon or a Threat 16 Leading Companies in Molecular Diagnostics Market 16 Antibiotic Resistant Bacteria Throws the Spotlight On Microbial Testing 16 Instant Detection of Pathogens - A New Epoch in the Fight for Survival 17 Lower Cost Rapid Tests Built on Multiple Sampling Modalities - Gaining Momentum 17 "Time Constraints?" - Rapid Tests to the Rescue 17 Rapid HIV Tests: A New Age Diagnostic Weapon Against the Killer Disease 18 Accuracy/Reliability of Home HIV Testing: A Bone of Contention 18 Development of Near Patient Test Kits: A Market Driven Phenomenon 19 Near Patient Test Kits: A Rumination of Possibilities 19 Automated Blood Culture Systems: A Winning Edge in the Fight Against Bacteremia 20 Leading Food Processors Resort to Rapid Microbiological Testing 20 Impact of Food Scares on Rapid Microbiological Tests Market 21 Demand for Microbiological Tests & Level of QC in the Food Industry 22 Rapid Tests Creating Brighter Avenues in Food Microbiology Testing Market 23 Dire Need to Nip Operating Costs Throws the Spotlight on Rapid Tests 23 Key Advantages/Benefits of Rapid Microbiological Tests on Food 24 Food Packages of the Future Ingrained with Microbial Alert Systems 24 Technology Innovations in Rapid Food Microbial Testing: A Historic Brief 24 Obtaining Regulatory Approval - A Major Non-Technical Hindrance 25 4. FACTORS INFLUENCING THE MARKET 26 Continuing Biological Warfare with Pathogens Sparks Market Growth 26 Innovative Products - A Key Growth Strategy 26 Other Market Drivers in a Capsule 26 Low Turnaround Times Skyrocket Demand 26 Greater Patient Awareness 26 Rising Incidence of STDs Kindles Universal Market Acceptance 27 Ultra-Rapid HIV-Screening Tests- A Strong Fight against HIV- Epidemic 27 Validation of Rapid Microbiological Tests: An Imperative Prerequisite 27 Non-Conformance to Testing Requirements: A Weighty Concern 28 Influenza - Boosting Rapid Test Prospects 29 5. PRODUCT/TECHNOLOGY OVERVIEW 30 Automated & Rapid Microbiological Tests: A Definition 30 Benefits of Automated & Rapid Microbiological Tests 30 Classification of Rapid Microbiological Test Methods 31 How Does a Rapid Test Work? 31 Sample Preparation - A Key Procedure 32 Automated Identification and Susceptibility Systems 32 Automated Blood Culture Systems 33 Automated Tuberculosis Systems 33 Microminiaturization of Diagnostic Tests: How Is It Effected? 33 Advantages of Microminiaturisation: 34 Acid-Fast Microscopy - The Forerunner of Rapid Tests 34 Gram's Stain: A Time-Honored & Rapid Method to Detect Pathogens in Blood 34 Enabling Technologies of Automated & Rapid Microbiological Tests 35 Growth-based Technologies 35 Viability-based Technologies 35 Cellular-Component or Artifact-based Technologies 36 Genomics/ Proteomics 36 Microarrays/Microfluidics 36 DNA Microchips/Probes 37 Polymerase Chain Reaction (PCR) 37 Immunoassay 38 Immunoassay Escalates into Diverse Fields of Diagnostic Testing 38 Nucleic Acid Testing (NAT) 38 Nucleic Acid Probes 39 Signal-Amplified Tests 39 Nucleic Acid Amplification Tests 39 Traditional Methods with Computer-Aided Imaging 40 Combination Methods 40 6. END-USE APPLICATION ANALYSIS 41 Applications in Clinical Investigations 41 STD Rapid Tests 41 GC/Chlamydia Rapid Tests 41 HIV Rapid Tests 42 HIV Facts & Figures 43 Table 4: Global Prevalence of HIV Infection by Region: 2007 & 2008 (includes corresponding Graph/Chart) 43 Table 5: Global HIV Related Deaths by Region: 2007 & 2008 (includes corresponding Graph/Chart) 44 Table 6: Global Distribution of HIV Prevalence, Incidence and Mortality: 2008 (includes corresponding Graph/Chart) 45 Advantages of Rapid HIV Testing 45 Disadvantages of Rapid HIV Testing 45 Syphilis Rapid Tests 46 Respiratory Rapid Tests 46 RSV/ Influenza Rapid Tests 46 Tuberculosis Rapid Tests 47 Group A beta Hemolytic Streptococcus Rapid Tests 47 Mononucleosis Rapid Tests 47 Streptococcus Rapid Tests 48 Streptococcus A Rapid Tests 48 Streptococcus B Rapid Tests 48 Gastrointestinal Rapid Tests 49 Giardia Lamblia Rapid Tests 49 H. Pylori Rapid Tests 49 Cryptosporidium Rapid Tests 50 C. Difficile Rapid Tests 50 Applications in Non-Clinical Investigations 50 Food/Water Safety Tests 51 Food Safety Testing: A Lucrative Application Area 51 Rapid Microbiological Methods in Pharmaceutical Sector 52 Limitations of RMMs 52 Advantages of RMMs 53 Applications in Pharmaceutical Sector 53 Environmental Tests 53 Other Miscellaneous Applications 54 7. PRODUCT INNOVATIONS/INTRODUCTIONS 55 BioControl Systems Develops PCR for Detecting Non-O157 Serotypes of STEC 55 InDevR Introduces New Virus Counter 55 MicroPhage Receives Approval from FDA for KeyPathâ„¢ MRSA/MSSA Blood Culture Test - BT 55 Health Canada Approves DuPont's BAX® System Real-Time Assay 56 Neogen Receives Approval from AOAC for Reveal 2.0 Test 56 Life Technologies and University of Pennsylvania School of Veterinary Medicine Introduce TaqMan® Salmonella enteritidis Detection Kit 56 AdvanDX Obtains 510(k) Clearance from US FDA for GNR Traffic Lightâ„¢ PNA FISH® 56 Pall Introduces GeneDisc Rapid Microbiology System 56 Abbott Laboratories Introduces PLEX-IDâ„¢ Biothreat Assay 57 bioMerieux Receives FDA Clearance for NucliSENS EasyQ MRSA 57 BD Launches BD Maxâ„¢ Open System 57 Luxcel Biosciences and Mocon Develop GreenLightâ„¢900 Series 58 Bruker Launches pTDâ„¢ for Homeland Security 58 Hygiena International Launches EnSURE 58 Researchers at University of Georgia Develop Pneumonia Diagnostic Test 59 BD Diagnostics Obtains Approval from FDA for BD MAXâ„¢ GBS Assay 59 bioMérieux Receives Approval for TEMPO® STA from AOAC and AFNOR 59 Bruker Introduces MALDI Sepsityperâ„¢ Kit 59 AdvanDx Introduces GNR Traffic Lightâ„¢ PNA FISH® 59 ZyGEM Launches Microbial Fingerprinting Diagnostic Technology 60 BD Diagnostics Launches BD BACTECâ„¢ MGITâ„¢ 320 Mycobacteria Culture System 60 Particle Measuring Systems Launches BioLazâ„¢ Real-Time Microbial Monitor 60 NanoLogix Launches Quick-Test Product Line 61 MOCON Introduces GreenLightâ„¢ Screening System 61 Life Technologies Unveils MicroSEQ® Rapid Microbial Identification System 61 IDEXX Laboratories Launch Enterolert®-DW in Europe 61 Alere Rolls Out three Cardiac Testing Solutions 62 Millipore Introduces New Milliflex Quantum Rapid Microbiological Test Method 62 BD Diagnostics Adds Automated Microbiology Specimen Processor to its Diagnostic Portfolio 62 Roche Introduces New Automatic Clinical Laboratory System, Cobas®4800 63 Thermo Fisher Scientific Launches an Automated Photometric Method 63 Thermo Fisher Scientific Introduces Salmonella Rapid Culture Method 63 BD Receives FDA Clearance for BD ProbeTec Amplified DNA Assays on BD Viper System 64 Oxoid Introduces Xpect® Flu A&B 64 Oxoid Extends ProSpecT Range 64 Oxoid Launches ELISA Systems Test Kits Range 65 Oxoid Introduces Brilliance VRE Agar and Brilliance ESBL Agar 65 Oxoid Launches RapID Kits 66 Inverness Medical Innovations Introduces C. DIFF QUIK CHEK COMPLETETM Rapid Test 66 Celsis International Launches Celsis ReACTTM 67 Roche Diagnostics Introduces LightCycler® Mycobacterium Detection Kit 67 bioMérieux Introduces NucliSENS EasyQ® HIV-1 v2.0 68 Celsis International Unveils RapiScreenTM Beverage 69 Siemens Launches MicroScan Synergies plus® gram-positive ID/ MIC and MIC Combination Panels 69 Oxoid Introduces IDEIATM Norovirus 69 Oxoid Introduces Salmonella PrecisTM Process 70 Remel Offers FDA Approved RPMI 1640 Agar w/MOPS and 2% Glucose 70 Oxoid Launches Rapid MDG Broth 70 Lonza Introduces microCompass TYMC (Total Yeast and Mould Count) Detection Kit 71 Inverness Medical Introduces Determine HIV-1/2 Ag/Ab Combo 71 Meridian Bioscience Rolls Out Two New Rapid Tests for Detecting Epstein-Barr Virus 72 Oxoid Introduces Staph Plus System for Identifying Staphylococcal Species 72 8. PRODUCT INNOVATIONS/INTRODUCTIONS IN RECENT PAST - A PERSPECTIVE BUILDER 73 Siemens Healthcare Diagnostics Launches MicroScan® WalkAway® plus Diagnostic Microbiology Systems 73 Bio-Rad Launches a Rapid test for Screening MRSA, MRSASelectâ„¢ test, in US 73 bioMérieux Introduces VIDAS®, an automated Clostridium difficile A & B Toxins Detection Test 73 Oxoid Launches Remel Wellcolex® Colour Tests for Testing Shigella, E. coli O157 and Salmonella 74 Siemens Healthcare Diagnostics Obtains Health Canada Approval for its VERSANT 440 Molecular System 74 Oxoid Unveils Remel Xpectâ„¢ Clostridium Difficile Toxin A/B Test 74 Neogen Introduces Soleris System 74 ATCC Introduces Authenticultâ„¢ Quality Control Microbiological Testing Tool 75 Bio-Rad Introduces New EBV Kits 75 Roche Seeks FDA Marketing Approval for Hepatitis C Virus Test 75 Roche Seeks US FDA Approval for its Cobas TaqScreen MPX Test 75 FDA Clears Usage of TIGRIS® System for Testing WNV in Donated Blood 76 FDA Approves ImmunoCard STAT!® EHEC for Detecting E. coli Infection 76 bioMérieux Introduces TEMPO® Quality Indicator Testing System 76 Biotrace Introduces Tecra Unique Campylobacter Rapid Test 76 bioMérieux Introduces TEMPO® EB test for Enterobacteriaceae 77 Roche Unveils Elecsys TORCH Assays 77 Roche Diagnostics Introduces Cobas TaqMan MTB Test in Japan 77 bioMérieux Develops Advanced Colorimetryâ„¢ NH Card 77 Roche Introduces Rapid LightCycler SeptiFast Sepsis Test across EU 78 Oxoid Launches New Rapid Test for Salmonella Detection in Food Products 78 Oxoid Unveils New Contact Plate Design 78 FDA Approves Fluconazole Susceptibility Tests from BioMérieux 78 Polysciences Unveils New Microbiological & Bacterial Detection Applications 79 Researchers Develop New Rapid MODS Test for TB Detection 79 Dade Behring Unveils Automated Quadriga BeFree System 79 FDA Approves Abbott PRISM® HBsAg Assay 79 Bayer's EHIV Test Receives FDA Clearance 80 Gen-Probe Obtains FDA Approval to Use Aptima Test on Additional Specimens 80 Roche Diagnostics' cobas TaqScreen MPX Test Receives CE Mark Approval 80 Cepheid Introduces Rapid Xpert® MRSA Test in Europe 80 Bio-Rad Widens Culture Media with Addition of RAPID'Salmonella 81 Chemogen Develops New Tuberculosis Rapid Test 81 bioMerieux Rolls Out VIDAS® LDUO Test 81 Zonda Develops New Rapid Test for Chlamydia 81 MedMira Launches MiraCare Rapid HIV Test 81 STMicroelectronics and Mobidiag Unveil Lab-On-Chip 82 Vermicon Launches ScanVIT-Legionella Rapid Test Kit 82 New Line of Rapid Microbial Detection Systems from Centrus 82 OraSure Rolls Out OraQuick ADVANCE 82 Abbott Unveils Automated HCV Test 82 ViroMed Rolls Out Rapid PCR Tests for Detecting Influenza and Respiratory Pathogens 83 Biophage Pharma Offers Service for Microbiological Testing 83 bioMerieux Releases New Rapid Test for Nosocomial Infections 83 bioMerieux Widens Product Portfolio with Addition of TEMPO® System 83 9. RECENT INDUSTRY ACTIVITY 84 Sekisui Chemical Acquires Diagnostic Products Business of Genzyme 84 Dynacare Laboratories Acquires Bruker MALDI Biotyper System 84 Magellan Biosciences Enters into Partnership with miacom Diagnostics 84 Lonza Signs Distribution Agreement with Roche 84 BD Enters into Collaboration with Bruker Daltonics 85 Seegene Enters into Partnership with Molzym 85 bioMérieux Enters into Partnership with Shanghai Institutes for Biological Sciences 85 Becton, Dickinson and Company Acquires Global Rights to Market Micro PRO 85 Rapid Micro Biosystems Enters Into Partnership with Life Technologies 86 DuPont and U.S. Department of Agriculture to Collaborate for New Microbiological Test 86 bioMérieux and Biocartis Enter into Partnership 86 BD Diagnostics Collaborates with Lonza Group 86 Rapid Micro Biosystems Signs Contract with BARDA 87 Shimadzu and bioMérieux Enter into Partnership 87 Micro Identification Technologies and OSI Optoelectronics Sign Agreement 87 Inverness Medical Adopts New Corporate Identity 87 Thermo Fisher Acquires Ahura Scientific 87 Don Whitley Signs Distribution Agreement with Zisys 88 Charm Sciences Acquires MLX Microplate Luminometer Product Line from Dynex Technologies 88 Alpha Analytical Acquires Boston Analytical Inc. 89 Roche Group Acquires Genentech 89 Roche Acquires Innovatis AG 89 3M Takes Over Biotrace International 89 Lab21 Buys Majority Stake in Biotec Laboratories 90 Vacci-Test Acquires Maxivet 90 bioMerieux Acquires PML Microbiologicals 90 3M Acquires Food Diagnostics AS 91 Becton, Dickinson and Company Receives License for its GeneOhmTM from Health Canada 91 BD Diagnostics Receives CE Marking for BD GeneOhmTM VanR Test 91 bioMérieux Bags AOAC Research Institute's Performance- Tested Methods SM Approval 92 MedMira Receives Sales Approval of Multiplo HBV/HIV/HCV Rapid Tests Market 92 Schering-Plough Inks International Collaboration Agreement with OraSure Technologies 92 Roche Selects Quidel's Influenza Test 93 Quidel Enters into Global Alliance with bioMerieux 93 Premier's QUEST Selects Remel SpectraTM MRSA 93 Thermo Fisher Scientific and MedAssets Supply Chain Systems Enter into a Supply Agreement 93 Thermo Fisher Scientific Bags FDA Approval for SpectraTM MRSA 94 Advantest to Take Over Credence Systems 94 DSM Food Specialties to Acquire CMT Srl 94 Sysmex Signs Agreement with bioMerieux 94 Nanogen Enters into Definitive Agreement with Elitech Group 95 Silliker Acquires Majority Stake in EGI Laboratory 95 BD Establishes New Rapid Diagnostic Products Manufacturing Facility in China 95 Quidel Corporation Obtains CLIA Waiver from US FDA for its QuickVue(R) RSV Test 96 Siemens Obtains US FDA Approval for its VERSANTâ„¢ 440 Molecular System 96 bioMérieux to Market Wescor's Customized Slide Stainer Instruments under bioMérieux Brand 96 Schering-Plough and OraSure Ink Collaboration Agreement for Developing Rapid Oral HCV Test 96 Abbott Obtains US FDA Approval for its Automated HTLV-I/HTLV- II Blood Screening Test 97 Quidel and bioMérieux Form a Long-term Alliance in Rapid Diagnostic Tests 97 BD Diagnostics Obtains US FDA Approval for BD GeneOhmâ„¢ StaphSR Assay 97 10. CORPORATE ACTIVITY IN RECENT PAST - A PERSPECTIVE BUILDER 98 Siemens Acquires Dade Behring 98 Concateno Acquires Euromed 98 Meridian Bioscience Obtains US FDA Approval for Two New Rapid Tests 98 Thermo Fisher Scientific Teams Up with KBA for Expanding its Microbiology Business Division in Lenexa 98 OraSure and SCMS Enter into an Agreement for Supplying OraQuick(R) HIV Test to PEPFAR Countries 99 Abbott Obtains US FDA Approval for its Fully Automated PRISM® HCV Test 99 Gen-Probe Obtains US FDA Approval for its PROCLEIX® TIGRIS® System for Testing Donated Blood 99 AdvanDx Ropes In bioMérieux for Distributing its Rapid Diagnostic Tests in US 99 3M and Gen-Probe Join Hands to Develop Rapid Molecular Tests For Detecting HAIs 100 Gen-Probe's PROCLEIX® TIGRIS® System Obtains US FDA Approval for Screening Donated Blood for West Nile Virus 100 3M Acquires Acolyte Biomedica 100 Formation of Siemens Medical Solutions Diagnostics 101 bioMérieux Bags Contract to Provide VITEK® 2 System for Scottish NHS Labs 101 bioMérieux Licenses NorChip's HPV Test Technology for Cervical Cancer 102 bioMérieux in Strategic Agreement with Cepheid for Sepsis Assays 102 3M Health Care Creates New Medical Diagnostics Unit 102 Schering-Plough & OraSure to Develop Rapid Oral HCV Test 103 3M Acquires Biotrace International 103 Siemens Acquires DPC 103 Oxoid Acquires Microbiology Business Activities of Dako 104 Inverness Acquires IDT and Thermo BioStar 104 BMD in Agreement with MND for Research on Diagnostic Tests 104 Cepheid Wins CDC Contract to Develop Rapid Bird Flu Virus Detection Test 104 Dutch Government Grants €7.9 Million to FIND 105 FIND and Hain to Develop Rapid Test for MDR and XDR TB 105 3M & Gen-Probe Ally for Developing Rapid Molecular Tests for Food Safety 105 Bio View Inks Three-Year Distribution Agreement with Abbott Molecular 106 Bodycote Acquires Foodscan Laboratories 106 Cepheid Bags STTR Funding for Development of Rapid TB Test 106 Abbott and Verax in Distribution Agreement for Verax Platelet PGD® Test 107 BSL Supplies ABBOTT PRISM® System to Blood Donor Testing Centers 107 Abbott & ARC in Agreement for Automated Blood Screening Tests 107 BD to Set Up Production Facility for Rapid Diagnostic Products in China 108 BD Diagnostics Delivers STI Testing Products to BioReference 108 Meridian Licenses LAMP Diagnostic Test Technology from Eiken 108 OraSure Inks Multi-Year Purchase Contract with New York City 108 Abbott Inks Single-Source Agreement with Novation for HIV Test 109 Neogen Takes Over Centrus International 109 Becton, Dickinson and Company Acquires GeneOhm Sciences 109 Inverness Medical Innovations Makes a Synergetic Purchase of ACON Laboratories 109 Quest Diagnostics Strikes Deal with BD Diagnostics 110 Novation Inks Pact with Abbott for Rapid HIV-1/2 Antibody Test 110 TREK Diagnostic and Novation Inks Agreement 110 Clinton Foundation Inks Agreement with Four Companies to Cut Prices 110 Chembio Obtains FDA Approval for HIV 1/2 Stat-Pak and Sure Check HIV 1/2 Rapid Test PMAs 110 Roche's LightCycler SeptiFast Test Attains CE Mark 111 Zonda Expands Distribution of Products in Europe 111 OraSure Wins Rapid HIV Tests Order 111 MedMira Secures Orders for Rapid HIV Tests 111 Cepheid Collaborates with Foundation for Innovative Diagnostics 111 Chembio Obtains Clearance for Rapid HIV Tests in Kenya 112 Genesis Bioventures Bags US Patent for Rapid Prion- Detection Assay 112 MedMira Obtains CE Mark for MiraCare 112 Setema to Distribute Chembio's Rapid HIV Tests in Ethiopia 112 Clinton Foundation HIV/AIDS Initiative Selects Chembio to Provide Rapid HIV Tests 112 Quidel Acquires immunochemical Fecal Occult Blood Test 112 Xact Aid Snaps Up STD Alert 112 Grant Life Sciences Acquires Rapid Tests from AccuDx 113 Millipore Ties Up with Gen-Probe 113 Foundation for Innovative New Diagnostics forms Collaboration with Eiken Chemical 113 WayPoint and Global Rapid Diagnostic Leader Enter into an Agreement 113 Akers Biosciences Enters into a Distribution Agreement with Alco Industries 113 Celsis and BioVentures Enter into Licensing Agreement 114 Thermo Electron Inks Pact with Genomic Profiling Systems 114 Abbott and OraSure Enters into Agreement for OraQuick ADVANCE Rapid HIV-1/2 Test 114 bioMérieux Signs Agreement with Novel Diagnostics 114 Dade Behring Bags FDA Approval for Antimicrobial Susceptibility Test Panels 114 OraSure Bags HCV Patent License from Chiron and Ortho- Clinical Diagnostics 115 BD Diagnostics Receives FDA Approval for BD Directigenâ„¢ EZ Flu A+B Test 115 BD Diagnostics Bags FDA Clearance for BBLâ„¢ CHROMagarâ„¢ MRSA Product 115 MedMira Obtains Rights to Market Rapid HIV Tests in Guizhou Province, China 115 Gen-Probe Obtains FDA Clearance for PROCLEIX® West Nile Virus Assay 115 Medical Services International Secures Clearance for Rapid Test Kits 115 Medical Services International Receives Exclusive Marketing Rights for TB Test Kit 115 Adaltis Receives Orders for HIV Rapid Tests from China 116 MedCap Bags Exclusive Distribution Rights for Syphilis Rapid Test 116 Genomic Profiling Systems Obtains NIAID Funds to Develop Testing Platform 116 Gen-Probe Obtains US Patent for Automated Process for Nucleic Acid Testing 116 Bio-Rad Receives Approval for HIV-1/HIV-2 Rapid Test 116 11. FOCUS ON SELECT GLOBAL PLAYERS 117 Abbott Laboratories (USA) 117 Abbott Diagnostics (USA) 117 Alere Inc. (US) 117 Becton Dickinson and Company (USA) 118 bioMerieux SA (France) 118 bioMerieux, Inc. (USA) 119 Bio-Rad Laboratories, Inc (USA) 119 Cellabs Pty Ltd (Australia) 119 Celsis International Plc (UK) 120 Coris BioConcept (Belgium) 120 F. Hoffmann-La Roche Ltd. (Switzerland) 120 Gen-Probe Inc. (USA) 121 MedMira, Inc. (Canada) 121 Meridian Biosciences, Inc. (USA) 122 Orasure Technologies, Inc. (USA) 122 Orion Diagnostica Oy (Finland) 122 Quidel Corp. (USA) 123 Sekisui Diagnostics (Japan) 123 Siemens Healthcare Diagnostics, Inc. (USA) 124 Thermo Fisher Scientific, Inc. (USA) 124 Remel, Inc. (USA) 124 Oxoid Limited (UK) 125 12. GLOBAL MARKET PERSPECTIVE 126 Table 7: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 126 Table 8: World Historic Review for Automated and Rapid Microbiological Tests by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 127 Table 9: World 15-Year Perspective for Automated and Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 128 Table 10: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 129 Table 11: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 130 Table 12: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 131 Table 13: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 132 Table 14: World Historic Review for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 133 Table 15: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Clinical Applications by Equipment Used - Percentage Breakdown of Revenues for Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests and Other Automated & Rapid Microbiological Tests for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 134 Table 16: World Recent Past, Current & Future Analysis for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 135 Table 17: World Historic Review for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 136 Table 18: World 15-Year Perspective for Automated Identification & Susceptibility Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart) 137 Table 19: World Recent Past, Current & Future Analysis for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 138 Table 20: World Historic Review for Automated Blood Culture Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 139 Table 21: World 15-Year Perspective for Automated Blood Culture Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 140 Table 22: World Recent Past, Current & Future Analysis for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 141 Table 23: World Historic Review for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 142 Table 24: World 15-Year Perspective for Automated Tuberculosis Systems in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 143 Table 25: World Recent Past, Current & Future Analysis for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 144 Table 26: World Historic Review for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 145 Table 27: World 15-Year Perspective for Streptococcal Infection Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 146 Table 28: World Recent Past, Current & Future Analysis for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 147 Table 29: World Historic Review for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 148 Table 30: World 15-Year Perspective for GC/Chlamydia Rapid Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 149 Table 31: World Recent Past, Current & Future Analysis for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 150 Table 32: World Historic Review for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 151 Table 33: World 15-Year Perspective for Other Automated & Rapid Microbiological Tests in Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 152 Table 34: World Recent Past, Current & Future Analysis for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 153 Table 35: World Historic Review for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - US, Europe, and Rest of World Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 154 Table 36: World 15-Year Perspective for Automated and Rapid Microbiological Tests in Non-Clinical Applications by Geographic Region - Percentage Breakdown of Revenues for US, Europe, and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 155 13. THE UNITED STATES 156 A.Market Analysis 156 A Current & Future Analysis 156 Rapid Microbiology Tests - A Competitive Profile 156 Consolidation in the Automated and Rapid Microbiological Tests Market 156 Bioterrorism Tests - Gaining Prominence 157 Tracking Trends Across Product Segments 157 STD Rapid Tests 157 Market Share Trends of Leading Players 157 Table 37: Leading Players in the US Market for GC/Chlamydia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe, Abbott, Becton Dickinson and Roche (includes corresponding Graph/Chart) 158 Table 38: Leading Players in the US Market for Chlamydia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Thermo Fischer Scientific, Alere ,and Quidel (includes corresponding Graph/Chart) 158 Table 39: Leading Players in the US Market for Syphilis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Alere, and Others (includes corresponding Graph/Chart) 158 Leading Players in HIV Rapid Testing Market 158 Gastrointestinal Rapid Tests 159 Market Share Data of Leading Players 159 Table 40: Leading Players in the US Market for C. Difficile Rapid Tests (2010) -Percentage Breakdown of Value Sales by Company for Alere, Meridian Biosciences, BioSite, Becton Dickinson, Thermo Fischer Scientific, and Others (includes corresponding Graph/Chart) 159 Table 41: Leading Players in the US Market for Cryptosporidium Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes correspondingGraph/Chart) 159 Table 42: Leading Players in the US Market for Rotavirus Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, Thermo Fisher Scientific, and Others (includes corresponding Graph/Chart) 160 Table 43: Leading Players in the US Market for Giardia Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Remel, Meridian Biosciences, and Becton Dickinson (includes corresponding Graph/Chart) 160 Respiratory Rapid Tests 160 Competition 160 Market Share Data of Leading Players 161 Table 44: Leading Players in the US Market for Influenza Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Quidel, Becton Dickinson, Thermo Fischer Scientific and Others (includes corresponding Graph/Chart) 161 Table 45: Leading Players in the US Market for RSV Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Becton Dickinson, Binax,,Thermo Fischer Scientific and Others (includes corresponding Graph/Chart) 161 Table 46: Leading Players in the US Market for Tuberculosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Gen-Probe and Becton Dickinson (includes corresponding Graph/Chart) 161 Table 47: Leading Players in the US Market for M. Pneumoniae Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Meridian Biosciences, and Remel, Inc. (includes corresponding Graph/Chart) 162 Table 48: Leading Players in the US Market for Mononucleosis Rapid Tests (2010) - Percentage Breakdown of Value Sales by Company for Alere, Remel, Quidel, and Others (includes corresponding Graph/Chart) 162 Streptococcus Infection Rapid Tests 162 Market Share Data of Leading Players 163 Table 49: Leading Players in the US Market for Streptococcus A Rapid Tests (2010) -Percentage Breakdown of Value Sales by Company for Quidel, Thermo Fischer Scientific, Becton Dickinson, and Others (includes corresponding Graph/Chart) 163 A Peek into the Testing Practices of the US Food Industry 163 B.Market Analytics 164 Table 50: US Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non- Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 164 Table 51: US Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification& Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 165 Table 52: US 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart) 166 Table 53: US Recent Past, Current & Future Analysis for Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart) 167 Table 54: US Historic Review for Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 168 Table 55: US 15-Year Perspective for Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Streptococcus Infection Rapid Tests {Streptococcus A, and Streptococcus B}, STD Rapid Tests {GC/Chlamydia, HIV, and Syphilis}, Respiratory Rapid Tests {RSV, Mononucleosis, Tuberculosis, Mycoplasma Pneumoniae, Legionella, and Influenza} and Gastrointestinal Rapid Tests {Cryptosporidium, Giardia, Rotavirus, C. Difficile, and H. Pylori}) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart) 169 14. EUROPE 170 A.Market Analysis 170 A Current & Future Analysis 170 European Market Primer 170 What Drives the Requirement Patterns of End-Users? 170 Competitive Profile 171 Trends & Issues 171 Proliferation of Automated, and Rapid Tests in Europe 171 European Automated Market 172 Probe Tests: "A Crack in the Future of Rapid Tests" 172 Trends Across Product Segments 172 GC/Chlamydia Rapid Tests 172 Streptococcal Infection (Strep A) Rapid Tests 172 Automated Tuberculosis Systems Market 172 B.Market Analytics 173 Table 56: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 173 Table 57: European Historic Review for Automated & Rapid Microbiological Tests by Geographic Region - France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 174 Table 58: European 15-Year Perspective for Automated & Rapid Microbiological Tests by Geographic Region - Percentage Breakdown of Revenues for France, Germany, The United Kingdom, Italy, Spain, Russia, & Rest of Europe for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart) 175 Table 59: European Recent Past, Current & Future Analysis for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart) 176 Table 60: European Historic Review for Automated & Rapid Microbiological Tests by End-Use Segment - Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications Independently Analyzed with Annual Revenues in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart) 177 Table 61: European 15-Year Perspective for Automated & Rapid Microbiological Tests by End-Use Segment - Percentage Breakdown of Revenues for Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, and Other Automated & Rapid Microbiological Tests) and Non-Clinical Applications for 2003, 2010 & 2017 (includes corresponding Graph/Chart) 178<b To order this report: In Vitro Diagnostic Industry: Global Automated and Rapid Microbiological Tests Industry Check our Industry Analysis and Insights Nicolas Bombourg SOURCE Reportlinker
|
|
||||||||
